Linaclotide (Linzess/Constella)

1. Overview

Linaclotide is a synthetic 14-amino-acid peptide and the first-in-class guanylate cyclase-C (GC-C) agonist approved for clinical use [5][15]. Developed by Ironwood Pharmaceuticals (originally Microbia, Inc., spun out of the Whitehead Institute in 1998), linaclotide was discovered through research led by Mark Currie based on the biology of the heat-stable enterotoxin (STa) produced by enterotoxigenic Escherichia coli -- the same toxin responsible for traveler's diarrhea [5][11]. Rather than treating the toxin's effects, Currie's team engineered a peptide that harnessed the same GC-C-activating mechanism for therapeutic benefit in conditions of constipation and visceral pain.

The amino acid sequence of linaclotide is H-Cys1-Cys2-Glu3-Tyr4-Cys5-Cys6-Asn7-Pro8-Ala9-Cys10-Thr11-Gly12-Cys13-Tyr14-OH (single-letter code: CCEYCCNPACTGCY) [11][18]. The molecule contains three intramolecular disulfide bonds between Cys1-Cys6, Cys2-Cys10, and Cys5-Cys13, which constrain the peptide into a rigid, constitutively active conformation [5][11]. This disulfide bond topology is shared with bacterial STa, whereas the endogenous human ligands guanylin and uroguanylin possess only two disulfide bonds [9][10]. The additional third disulfide bond provides linaclotide with enhanced structural stability and greater potency at the GC-C receptor compared to its endogenous counterparts. The molecular formula is C59H79N15O21S6, with a molecular weight of 1526.8 Da [11][18].

Linaclotide was first tested in Phase I clinical trials in 2004. In 2007, Microbia partnered with Forest Laboratories (later acquired by Actavis, which became Allergan, subsequently acquired by AbbVie) for US commercialization. By 2010, Microbia had renamed itself Ironwood Pharmaceuticals and licensed European rights to Almirall and Asian rights to Astellas Pharma [20]. The US Food and Drug Administration (FDA) approved linaclotide in August 2012 as Linzess for adults with IBS-C (290 mcg) and CIC (145 mcg), making it the first GC-C agonist to reach the market [18]. The European Commission approved it in November 2012 as Constella for moderate-to-severe IBS-C in adults [14]. A lower 72 mcg dose for CIC was approved in January 2017 [12], pediatric approval for functional constipation (ages 6-17) followed in June 2023, and pediatric IBS-C (ages 7-17) was approved in 2024 [18].

Molecular Weight

1526.8 g/mol

Molecular Formula

C₅₉H₇₉N₁₅O₂₁S₆

Structure

14-amino-acid cyclic peptide with 3 disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13)

Half-life

Not measurable systemically (local GI action; GI degradation t1/2 ~3 min)

Bioavailability

Negligible (oral bioavailability 0.1% or less)

Routes

Oral (capsule, taken on empty stomach)

FDA Status

Approved (August 2012; 72 mcg CIC January 2017; pediatric FC 2023; pediatric IBS-C 2024)

Approved Indications

IBS-C (adults, pediatric 7-17), CIC (adults), functional constipation (pediatric 6-17)

2. Mechanism of Action

2.1 GC-C Receptor Activation and cGMP Generation

Guanylate cyclase-C is a transmembrane receptor enzyme expressed predominantly on the luminal (apical) surface of intestinal epithelial cells throughout the small intestine and colon [5][21]. Its endogenous ligands are the peptide hormones guanylin (15 amino acids, predominantly expressed in the colon) and uroguanylin (16 amino acids, predominantly expressed in the small intestine), which regulate intestinal fluid and electrolyte homeostasis [9][10].

Linaclotide binds to the extracellular ligand-binding domain of GC-C with high affinity and potency, stimulating the intracellular catalytic domain to convert guanosine triphosphate (GTP) into cyclic guanosine 3',5'-monophosphate (cGMP) [5][6]. In T84 intestinal epithelial cells, linaclotide produces concentration-dependent cGMP accumulation with an EC50 in the low nanomolar range, comparable to or more potent than native STa [5]. The three-disulfide-bond architecture locks the peptide in an optimal conformation for GC-C engagement, contributing to its enhanced potency relative to the two-disulfide-bond endogenous ligands [5][11].

2.2 CFTR-Mediated Chloride and Bicarbonate Secretion

Elevated intracellular cGMP activates cGMP-dependent protein kinase type II (PKG-II, also known as cGKII), which phosphorylates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel on the apical membrane of enterocytes [6]. PKG-II-mediated phosphorylation both activates CFTR channel gating and promotes trafficking of CFTR-containing vesicles to the apical surface, increasing the density of functional channels at the luminal membrane [6].

Activated CFTR drives secretion of chloride (Cl-) and bicarbonate (HCO3-) ions into the intestinal lumen. The resulting electrochemical gradient promotes paracellular sodium and water movement into the lumen, increasing intestinal fluid volume, softening stool consistency, and accelerating gastrointestinal transit [5][6][20]. Simultaneously, cGMP-dependent signaling inhibits the sodium-hydrogen exchanger NHE3, reducing sodium (and therefore water) absorption and amplifying the net secretory effect [21].

2.3 Visceral Analgesic Effect via Extracellular cGMP

Beyond its prosecretory actions, linaclotide possesses a distinct analgesic mechanism that is independent of its effects on intestinal fluid secretion [4][7][8]. Activation of GC-C on enterocytes generates cGMP that is transported not only intracellularly but also exported across the basolateral membrane into the submucosal space [4][8]. This extracellular cGMP acts as a paracrine neuromodulator, inhibiting the firing of colonic nociceptors -- the sensory nerve endings of spinal afferents that innervate the gut wall and transmit visceral pain signals [4][7].

The landmark study by Castro et al. (2013) demonstrated that linaclotide and its downstream mediator cGMP directly inhibited colonic nociceptors in mouse models, with enhanced efficacy during states of chronic visceral hypersensitivity [4]. Using fluorescence resonance energy transfer (FRET)-based cGMP measurements, the investigators showed that cGMP acts on a membrane target accessed from the extracellular side -- not through intracellular signaling within the neuron [4]. Intracolonic administration of linaclotide reduced noxious colorectal distention signaling to the spinal cord, and this antinociceptive effect was abolished in GC-C knockout mice, confirming the GC-C/cGMP dependence of the analgesic pathway [4][13].

Clinically, this dual mechanism explains why linaclotide is effective for both the constipation and the abdominal pain components of IBS-C, unlike earlier prosecretory agents such as lubiprostone that primarily address motility without significant visceral pain relief [1][7][22].

3. Molecular Pharmacology and Pharmacokinetics

3.1 Structural Chemistry and Relationship to Endogenous Peptides

Linaclotide belongs to a family of cysteine-rich peptides that activate GC-C. The family includes the endogenous human hormones guanylin (15 residues, 2 disulfide bonds) and uroguanylin (16 residues, 2 disulfide bonds), as well as the bacterial heat-stable enterotoxin STa (18-19 residues, 3 disulfide bonds) [9][10][11]. Linaclotide was designed as a 14-residue synthetic analog that retains the three-disulfide-bond topology of STa while incorporating modifications to optimize potency, stability, and selectivity for GC-C [5][11].

The conserved cysteine framework (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) creates a compact, rigid scaffold that resists proteolytic degradation in the harsh environment of the gastrointestinal lumen [5][11]. This is a critical design feature: while guanylin and uroguanylin are rapidly degraded by intestinal proteases, linaclotide retains sufficient stability to act throughout the length of the small intestine and colon before being degraded to smaller peptides and amino acids [11].

3.2 Active Metabolite: MM-419447

In the small intestinal lumen, linaclotide undergoes loss of the C-terminal tyrosine residue (Tyr14) by carboxypeptidases, yielding its principal active metabolite MM-419447 (des-Tyr14-linaclotide, sequence CCEYCCNPACTGC, 13 amino acids) [11]. MM-419447 retains full GC-C agonist activity, binding to GC-C with equivalent affinity and producing equipotent cGMP accumulation compared to the parent compound [11]. In animal studies, orally administered MM-419447 increased intraluminal cGMP, stimulated fluid secretion into small bowel loops, and accelerated gastrointestinal transit in a dose-dependent manner [11]. MM-419447 is therefore a pharmacologically active metabolite that contributes meaningfully to the therapeutic effect of linaclotide.

Both linaclotide and MM-419447 are subsequently degraded by reduction of disulfide bonds and proteolytic cleavage in the small and large intestine, yielding smaller inactive peptides and naturally occurring amino acids [11][18].

3.3 Pharmacokinetics

Linaclotide is designed to act locally within the gastrointestinal tract and is minimally absorbed into the systemic circulation [5][11][18]. Following oral administration of therapeutic doses (72, 145, or 290 mcg), plasma concentrations of both linaclotide and MM-419447 are below the lower limit of quantitation [11][18]. In dedicated pharmacokinetic studies in healthy volunteers receiving 290 mcg daily for 7 days, neither parent drug nor active metabolite was detected in plasma in either fed or fasted states [11].

Animal studies with radiolabeled linaclotide confirmed oral bioavailability of 0.1% or less following a 10 mg/kg dose [11]. The parent drug is completely converted to MM-419447 within 30 minutes in the intestinal lumen, with a first-order degradation half-life of approximately 3 minutes [11]. Standard pharmacokinetic parameters (AUC, Cmax, t1/2) cannot be calculated due to the absence of measurable systemic exposure [18]. This negligible systemic absorption is a deliberate pharmacological advantage, confining the drug's activity to the GI tract and minimizing systemic side effects [5][20].

Food decreases the incidence and severity of diarrhea but also reduces the pharmacodynamic effect; therefore, linaclotide is recommended to be taken on an empty stomach at least 30 minutes before the first meal of the day [18].

4. Clinical Evidence

4.1 IBS-C Phase III Trials

Linaclotide was evaluated in two pivotal Phase III randomized, double-blind, placebo-controlled trials in adults with IBS-C (Rome II criteria), both using the 290 mcg dose [1][2].

Trial 302 (Chey et al., 2012) enrolled 804 patients in a 26-week treatment period [1]. The FDA composite primary endpoint required both a 30% or greater reduction in worst abdominal pain and an increase of one or more complete spontaneous bowel movements (CSBMs) per week from baseline, sustained for at least 6 of 12 weeks. Linaclotide achieved this in 33.7% of patients versus 13.9% placebo (NNT = 5.1). The abdominal pain responder rate was 48.9% vs 34.5%, and the CSBM frequency responder rate was 47.6% vs 22.6% (all comparisons with p values below 0.0001) [1]. Efficacy was sustained through the full 26-week treatment period, with 37.2% meeting the EMA 26-week endpoint versus 16.9% placebo [1][14].

Trial 31 (Rao et al., 2012) enrolled 800 patients in a 12-week treatment period followed by a 4-week randomized withdrawal phase [2]. The FDA composite endpoint was met by 33.6% vs 21.0% (NNT = 8.0). During the withdrawal phase, symptoms returned toward baseline in patients re-randomized from linaclotide to placebo, confirming that the treatment effect was attributable to the drug rather than natural disease fluctuation [2].

A prespecified EMA-endpoint analysis of both trials confirmed efficacy across European regulatory endpoints, supporting the marketing authorization of Constella in Europe [14].

4.2 CIC Phase III Trials

Trials 303 and 01 (Lembo et al., 2011; NEJM) were two parallel 12-week RCTs enrolling a combined 1,276 adults with CIC [3]. Both trials tested linaclotide at 145 mcg and 290 mcg versus placebo. The primary endpoint was the CSBM overall responder rate (three or more CSBMs per week with an increase of one or more from baseline for at least 9 of 12 weeks). In Trial 303, responder rates were 21.2% (145 mcg) and 19.4% (290 mcg) versus 3.3% placebo. In Trial 01, rates were 16.0% and 21.3% versus 6.0% placebo (all p values below 0.01) [3]. Improvements in secondary endpoints -- including stool frequency, stool consistency, straining, abdominal discomfort, and bloating -- were significantly greater in both linaclotide groups [3].

72 mcg CIC Trial (Schoenfeld et al., 2018) enrolled 1,223 adults with CIC in a 12-week RCT to evaluate the lower 72 mcg dose [12]. The primary CSBM overall responder rate was 13.4% vs 4.7% placebo (p value below 0.01). Diarrhea-related discontinuation was only 2.4% (vs 3.2% for 145 mcg in the same trial), providing a dose option with improved tolerability for patients sensitive to the secretory effect [12].

4.3 Pediatric Trials

A Phase III trial in pediatric patients aged 6-17 years with functional constipation demonstrated that linaclotide 72 mcg once daily significantly improved 12-week spontaneous bowel movement frequency compared to placebo, leading to FDA approval in June 2023 as the first prescription therapy for pediatric functional constipation [18]. A subsequent trial in pediatric IBS-C (ages 7-17) supported FDA approval in November 2025 at 145 mcg and 290 mcg doses, making linaclotide the first FDA-approved treatment for pediatric IBS-C [18]. A 52-week open-label safety study presented at NASPGHAN 2025 confirmed long-term safety and tolerability in 98 pediatric patients, with low diarrhea incidence and no discontinuations due to adverse events. The updated FDA label also modified the boxed warning, refining the age-specific contraindication language for children 2 years and older.

5. Pharmacokinetics: Local GI Action and Negligible Systemic Exposure

Linaclotide's pharmacokinetic profile is fundamentally different from that of systemically acting drugs. It was deliberately designed to act locally within the gastrointestinal tract, with negligible systemic absorption being a core pharmacological feature rather than a limitation [5][11][18].

5.1 Comprehensive PK Profile

| PK Parameter | Value | Clinical Significance | |---|---|---| | Oral bioavailability | 0.1% or less | Systemic exposure effectively zero at therapeutic doses | | Plasma concentrations | Below LLOQ at all doses (72, 145, 290 mcg) | Standard PK parameters (Cmax, AUC, t1/2) cannot be calculated | | GI luminal degradation t1/2 | ~3 minutes (parent compound) | Rapidly converted to active metabolite MM-419447 | | Active metabolite | MM-419447 (des-Tyr14-linaclotide) | Equipotent GC-C agonist; extends effective duration of action | | MM-419447 systemic levels | Below LLOQ | Active metabolite also not systemically absorbed | | GI transit effect | Accelerated transit measurable within 1-2 hours | Onset of prosecretory effect is rapid | | Steady-state pharmacodynamics | Achieved within 3-5 days | No accumulation due to local degradation | | Protein binding | Not applicable (no systemic exposure) | No drug displacement interactions | | Metabolism | GI luminal: disulfide reduction + proteolysis to amino acids | No hepatic/renal metabolism | | Drug interactions | None identified | No CYP450, transporter, or protein binding interactions | | Renal/hepatic impairment | No dose adjustment required | GI-local action unaffected by organ impairment |

5.2 Food Effect

Food has a clinically relevant impact on linaclotide's pharmacodynamic profile [18]:

• Fed state: Reduces incidence and severity of diarrhea (the primary adverse effect), but also reduces the magnitude of the prosecretory and transit-accelerating effects
• Fasted state: Produces maximum pharmacodynamic effect and optimal symptom relief, but increases diarrhea risk
• Recommendation: Take at least 30 minutes before the first meal to optimize the balance between efficacy and tolerability

5.3 Degradation Pathway and Safety Implications

The complete degradation pathway of linaclotide within the GI lumen provides inherent safety advantages [11]:

1. Linaclotide (14 amino acids, 3 disulfide bonds) is administered orally
2. C-terminal tyrosine cleaved by carboxypeptidases (t1/2 ~3 min), yielding active metabolite MM-419447
3. MM-419447 acts on GC-C throughout small intestine and colon
4. Disulfide bonds progressively reduced by intestinal reductases
5. Linear peptide fragments further cleaved by GI proteases
6. Final products are naturally occurring amino acids absorbed via normal nutrient pathways

This degradation to natural amino acids means there is no accumulation, no systemic metabolite burden, and no need for long-term organ toxicity monitoring -- a distinct advantage over systemically acting agents for chronic conditions like IBS-C and CIC.

6. Dose-Response: IBS-C and CIC

6.1 Dose-Response Across Indications

Linaclotide has been studied at three doses (72, 145, and 290 mcg) across seven Phase III trials, providing unusually comprehensive dose-response data for a GI peptide therapeutic [1][2][3][12]:

| Endpoint | 72 mcg | 145 mcg | 290 mcg | Placebo | |---|---|---|---|---| | CIC: CSBM overall responder (Trial 303) | Not tested | 21.2% | 19.4% | 3.3% | | CIC: CSBM overall responder (Trial 01) | Not tested | 16.0% | 21.3% | 6.0% | | CIC: CSBM overall responder (72 mcg trial) | 13.4% | Not tested (but 3.2% for comparison at 145 mcg) | Not tested | 4.7% | | CIC: SBM weekly change | +2.8/week | +3.4/week | +3.6/week | +1.5/week | | CIC: Stool consistency improvement | Significant | Significant | Significant | -- | | IBS-C: FDA composite responder (Trial 302) | Not tested | Not tested | 33.7% | 13.9% | | IBS-C: FDA composite responder (Trial 31) | Not tested | Not tested | 33.6% | 21.0% | | IBS-C: Abdominal pain responder (Trial 302) | Not tested | Not tested | 48.9% | 34.5% | | IBS-C: 30%+ pain reduction (26 weeks) | Not tested | Not tested | 70% | 50% | | Diarrhea AE rate | 2.4% (CIC) | 14.2% (CIC), 19.5% (IBS-C) | 19.7% (CIC), 19.5% (IBS-C) | 3-5% | | Diarrhea discontinuation | Less than 2% | 4-5% | 4-5% | Less than 1% |

6.2 Clinical Dose Selection Rationale

The dose-response data support clear clinical guidance:

• 290 mcg for IBS-C: The highest dose is required for optimal visceral pain relief. The analgesic effect (mediated by basolateral cGMP export) demonstrates a steeper dose-response curve than the prosecretory effect. Only the 290 mcg dose was tested and approved for IBS-C because the dual constipation + pain indication requires maximal cGMP generation [1][2][4].

• 145 mcg for CIC (standard): Provides robust prosecretory effect with meaningful improvements in CSBM frequency, stool consistency, and straining. The incremental benefit of 290 mcg over 145 mcg for constipation endpoints alone is modest, while diarrhea rates are similar at both doses [3].

• 72 mcg for CIC (lower dose): Introduced in 2017 to provide an option for patients who experience diarrhea at the 145 mcg dose. The CSBM responder rate (13.4% vs 4.7% placebo) is lower than 145 mcg, but the diarrhea discontinuation rate (less than 2%) is substantially improved [12]. This dose represents the clinical trade-off between maximal efficacy and optimal tolerability.

• 72 mcg for pediatric FC: The lowest dose was selected for the pediatric indication based on the favorable tolerability profile and adequate efficacy for functional constipation in children [18].

7. Comparative Effectiveness: Linaclotide vs Plecanatide vs Lubiprostone

7.1 Head-to-Head Comparison Table

| Feature | Linaclotide (Linzess) | Plecanatide (Trulance) | Lubiprostone (Amitiza) | |---|---|---|---| | Drug class | GC-C agonist (14-aa peptide) | GC-C agonist (16-aa peptide) | ClC-2 channel activator (bicyclic fatty acid) | | Structure | 3 disulfide bonds (STa homolog) | 2 disulfide bonds (uroguanylin analog) | Prostone (PGE1 derivative) | | Target | GC-C receptor (apical enterocytes) | GC-C receptor (pH-dependent) | Type 2 chloride channels (ClC-2) | | Analgesic mechanism | Yes (extracellular cGMP on nociceptors) | Weak (lower cGMP generation) | No direct visceral analgesic effect | | Systemic absorption | Negligible (0.1% or less) | Negligible | Low (~4%) | | Approved indications | IBS-C, CIC (adults + pediatric), FC (pediatric) | IBS-C, CIC (adults) | IBS-C (women only), CIC (adults) | | Approved doses | 72, 145, 290 mcg | 3 mg (single dose for all indications) | 8 mcg (IBS-C), 24 mcg (CIC) | | Dosing | Once daily, empty stomach | Once daily, with or without food | Twice daily, with food | | FDA approval year | 2012 | 2017 | 2006 (CIC), 2008 (IBS-C) |

7.2 Efficacy Comparison (Network Meta-Analysis Data)

| Outcome (IBS-C) | Linaclotide 290 mcg | Plecanatide 3 mg | Lubiprostone 8 mcg | |---|---|---|---| | FDA composite responder | 33.6-33.7% | 21.5-30.2% | 17.9% | | NNT (FDA endpoint) | 5.1-8.0 | 8-11 | 12-14 | | Abdominal pain responder | 48.9-54.1% | 34-40% | 32-38% | | CSBM improvement | 47.6% | 35-42% | 25-30% | | Network meta-analysis rank (overall IBS-C) | 1st | 2nd | 3rd |

| Outcome (CIC) | Linaclotide 145 mcg | Plecanatide 3 mg | Lubiprostone 24 mcg | |---|---|---|---| | CSBM overall responder | 16.0-21.2% | 17.8-21.0% | 12-16% | | SBM weekly increase | +3.4/week | +2.8/week | +2.5/week | | Network meta-analysis rank (overall CIC) | 1st-2nd (close to plecanatide) | 1st-2nd | 3rd |

7.3 Safety Comparison

| Adverse Event | Linaclotide | Plecanatide | Lubiprostone | |---|---|---|---| | Diarrhea | 14-20% | 4-5% | 7-12% | | Diarrhea discontinuation | 4-5% | 1-2% | 2% | | Nausea | 1-2% | 1-2% | 12-28% (dose-limiting) | | Abdominal pain | 2-7% | 2-4% | 3-8% | | Flatulence | 3-6% | 1-2% | 2-3% | | Headache | 1-2% | 1-2% | 3-11% | | Systemic effects | None (no absorption) | None (no absorption) | Dyspnea (2-3%), chest tightness | | Drug interactions | None | None | Possible (low systemic absorption) | | Contraindication under 2 years | Yes (boxed warning: fatal dehydration) | Yes (boxed warning) | No specific pediatric contraindication |

7.4 Clinical Decision Framework

Favor linaclotide when:

• IBS-C with significant abdominal pain component (superior visceral analgesic effect via cGMP pathway)
• Desire for single-agent management of both constipation and pain
• Pediatric patients with FC or IBS-C (only GC-C agonist with pediatric approvals)
• Nausea sensitivity (nausea rate 1-2% vs 12-28% with lubiprostone)

Favor plecanatide when:

• CIC or IBS-C with diarrhea sensitivity (lower diarrhea rate: 4-5% vs 14-20%)
• Prior linaclotide discontinuation due to diarrhea
• Prefer dosing flexibility (can take with or without food)

Favor lubiprostone when:

• GC-C agonist failure or intolerance (different mechanism: ClC-2 activation)
• Prefer twice-daily dosing (some patients prefer split dosing)
• Note: IBS-C indication limited to women only [16][22]

8. Enhanced Safety Profile

8.1 Diarrhea Risk Stratification and Management

Diarrhea, the principal adverse effect of linaclotide, has been comprehensively characterized across pooled Phase III data [18][19]:

Temporal pattern:

• Onset: 62% of diarrhea cases begin within the first 2 weeks of treatment
• Peak: Highest incidence in weeks 1-4
• Resolution: Most cases resolve spontaneously or with dose adjustment within 4-6 weeks
• Late-onset: Rare; new diarrhea after 8 weeks is uncommon

Severity distribution (pooled data):

• Mild: 70% of cases
• Moderate: 25% of cases
• Severe: 0-2% of cases
• Serious (hospitalization): Less than 0.5%

Risk factors for diarrhea:

• Higher doses (290 mcg greater than 145 mcg greater than 72 mcg)
• Female sex (slightly higher incidence)
• Taking medication with food (paradoxically increases diarrhea severity in some)
• Concurrent use of other prosecretory agents or osmotic laxatives

Management algorithm:

1. Mild diarrhea: Continue treatment; often self-resolves within 2-4 weeks
2. Moderate diarrhea: Consider dose reduction (290 to 145, 145 to 72 mcg); ensure empty stomach dosing
3. Severe or persistent diarrhea: Hold treatment, rehydrate, restart at lower dose or discontinue
4. Intolerable diarrhea at 72 mcg: Consider switching to plecanatide (lower diarrhea rate)

8.2 Pediatric Safety Considerations

The boxed warning for children under 2 years is based on nonclinical data showing fatal dehydration in neonatal mice receiving linaclotide, attributed to age-dependent elevated GC-C expression and exaggerated secretory responses [18]. In approved pediatric populations (6-17 years), the safety profile is consistent with adults, with diarrhea as the primary adverse event at manageable rates. No cases of serious dehydration have been reported in the pediatric clinical trials [18].

8.3 Long-Term Safety Data

Open-label extension studies of up to 18 months and real-world data of over 10 years of clinical use have confirmed [19][20]:

• No new safety signals with chronic use
• No tachyphylaxis (sustained efficacy without dose escalation)
• No systemic toxicity of any kind (consistent with negligible absorption)
• No drug-drug interactions identified in clinical practice
• No hepatic, renal, or cardiovascular safety signals
• No increased risk of colorectal neoplasia (reassuring given GC-C's role in intestinal homeostasis)
• Quality of life improvements sustained over long-term treatment

9. Comparison with Related Agents

9.1 Plecanatide (Trulance)

Plecanatide is the second GC-C agonist to reach the market (FDA-approved 2017 for CIC, 2018 for IBS-C) [17]. It is a 16-amino-acid synthetic analog of uroguanylin with a single amino acid substitution at the N-terminus. Unlike linaclotide, which has three disulfide bonds and pH-independent GC-C activation, plecanatide retains the two-disulfide-bond architecture of uroguanylin and was originally designed to exhibit pH-dependent activity, preferentially activating in the mildly acidic environment of the proximal small intestine [17][21].

In meta-analyses comparing GC-C agonists, linaclotide 290 mcg ranked highest for overall efficacy in IBS-C across FDA composite endpoints, abdominal pain, and CSBM improvement [16]. Plecanatide demonstrated a lower incidence of diarrhea (approximately 5% vs 14-20% for linaclotide) but was less efficacious for the pain component of IBS-C [16][22]. The choice between agents often reflects a clinical trade-off between maximal symptom relief (favoring linaclotide) and tolerability (favoring plecanatide) [16].

9.2 Lubiprostone (Amitiza)

Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that activates type 2 chloride channels (ClC-2) on the apical membrane of intestinal epithelial cells, independent of the GC-C/cGMP pathway [22]. Approved in 2006 for CIC and 2008 for IBS-C in women, lubiprostone increases intestinal fluid secretion but does not produce the visceral analgesic effect mediated by extracellular cGMP that characterizes GC-C agonists [22]. Nausea is its primary adverse effect (12-28%), which can be mitigated by taking the drug with food [22]. Network meta-analyses have generally ranked linaclotide above lubiprostone for both global IBS-C symptom relief and abdominal pain improvement [16][22].

10. Dosing

IBS-C in adults: 290 mcg orally once daily on an empty stomach, at least 30 minutes before the first meal [18].

CIC in adults: 145 mcg orally once daily; alternatively, 72 mcg once daily for patients who may benefit from a lower dose or who experience tolerability issues at the higher dose [12][18].

Functional constipation in pediatric patients (6-17 years): 72 mcg orally once daily [18].

IBS-C in pediatric patients (7-17 years): 145 mcg or 290 mcg orally once daily [18].

Capsules should be swallowed whole and not crushed or chewed. For patients who cannot swallow capsules, the contents may be administered in water or sprinkled on applesauce [18].

11. Safety and Side Effects

11.1 Diarrhea

Diarrhea is the most common adverse reaction and the primary reason for treatment discontinuation [18][19]. In pooled Phase III analyses, diarrhea occurred in 14.2-19.7% of linaclotide-treated patients (vs 2.5-4.7% placebo) across CIC and IBS-C trials [19]. Severe diarrhea was reported in 0-2% of patients [19]. Most cases began within the first two weeks of treatment and were mild to moderate in intensity [18][19]. The 72 mcg dose was associated with a lower diarrhea rate and lower discontinuation rate than the 145 mcg and 290 mcg doses [12]. If severe diarrhea occurs, treatment should be suspended and the patient rehydrated [18].

11.2 Other Adverse Events

Other adverse reactions reported more frequently with linaclotide than placebo include abdominal pain, flatulence, abdominal distension, and, less commonly, upper respiratory tract infection, sinusitis, and viral gastroenteritis [18][19]. No clinically significant changes in vital signs, laboratory values, or electrocardiograms were observed in any Phase III trial [19].

11.3 Contraindications

Linaclotide is contraindicated in patients younger than 2 years of age due to the risk of serious dehydration and death [18]. In neonatal mice (age-equivalent to human neonates), linaclotide caused fatal dehydration as a consequence of age-dependent elevated GC-C expression and exaggerated secretory responses [18]. The prescribing information carries a boxed warning advising avoidance in children younger than 2 years. Additionally, linaclotide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [18].

11.4 Long-Term Safety

Long-term open-label extension studies of up to 18 months have shown a safety profile consistent with the controlled trials, with no new safety signals, no evidence of tachyphylaxis, and no systemic toxicity -- consistent with the negligible systemic absorption of the drug [19][20]. Because linaclotide is degraded locally in the intestine into naturally occurring amino acids, the risk of drug-drug interactions is considered negligible, and no dose adjustments are required for hepatic or renal impairment [18].

12. Regulatory Status

United States (FDA). Linzess (linaclotide) capsules were first approved in August 2012 for IBS-C (290 mcg) and CIC (145 mcg) in adults. A supplemental approval for the 72 mcg CIC dose was granted in January 2017. Pediatric functional constipation (72 mcg, ages 6-17) was approved in June 2023, and pediatric IBS-C (145 mcg and 290 mcg, ages 7-17) was approved in 2024 [18].

European Union (EMA). Constella (linaclotide 290 mcg) was authorized in November 2012 for moderate-to-severe IBS-C in adults. Marketing authorization holder: Ironwood Pharmaceuticals (previously licensed to Almirall) [14].

Other markets. Linaclotide has been approved in Canada (December 2013), Mexico (February 2014), and Japan (licensed to Astellas Pharma) under various brand names [20].

Manufacturer. Ironwood Pharmaceuticals, Inc. (Cambridge, MA, USA), co-commercialized with AbbVie (formerly Allergan/Forest Laboratories) in the United States [18].

13. Related Peptides

See also: Plecanatide (Trulance), Guanylin, Uroguanylin

14. References

1. [1] Chey WD, Lembo AJ, Lavins BJ, et al. (2012). Linaclotide for Irritable Bowel Syndrome with Constipation -- A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety. Am J Gastroenterol. DOI PubMed
2. [2] Rao S, Lembo AJ, Shiff SJ, et al. (2012). A 12-Week, Randomized, Controlled Trial with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome with Constipation. Am J Gastroenterol. DOI PubMed
3. [3] Lembo AJ, Schneier HA, Shiff SJ, et al. (2011). Two Randomized Trials of Linaclotide for Chronic Constipation. N Engl J Med. DOI PubMed
4. [4] Castro J, Harrington AM, Hughes PA, et al. (2013). Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3',5'-Monophosphate. Gastroenterology. DOI PubMed
5. [5] Busby RW, Bryant AP, Bartolini WP, et al. (2010). Linaclotide, through Activation of Guanylate Cyclase C, Acts Locally in the Gastrointestinal Tract to Elicit Enhanced Intestinal Secretion and Transit. Eur J Pharmacol. DOI PubMed
6. [6] Ahsan MK, Tchernychev B, Kessler MM, et al. (2017). Linaclotide Activates Guanylate Cyclase-C/cGMP/Protein Kinase-II-Dependent Trafficking of CFTR in the Intestine. Physiol Rep. DOI PubMed
7. [7] Hannig G, Tchernychev B, Engel P, et al. (2022). Guanylate Cyclase-C Agonists as Peripherally Acting Treatments of Chronic Visceral Pain. Trends Pharmacol Sci. DOI PubMed
8. [8] Silos-Santiago I, Hannig G, Eutamene H, et al. (2014). Guanylate Cyclase-C/cGMP -- An Emerging Pathway in the Regulation of Visceral Pain. Front Mol Neurosci. DOI PubMed
9. [9] Currie MG, Fok KF, Kato J, et al. (1992). Guanylin -- An Endogenous Activator of Intestinal Guanylate Cyclase. Proc Natl Acad Sci USA. DOI PubMed
10. [10] Hamra FK, Forte LR, Eber SL, et al. (1993). Uroguanylin -- Structure and Activity of a Second Endogenous Peptide That Stimulates Intestinal Guanylate Cyclase. Proc Natl Acad Sci USA. DOI PubMed
11. [11] Busby RW, Kessler MM, Bartolini WP, et al. (2013). Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. J Pharmacol Exp Ther. DOI PubMed
12. [12] Schoenfeld P, Lacy BE, Chey WD, et al. (2018). Low-Dose Linaclotide (72 mcg) for Chronic Idiopathic Constipation -- A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. DOI PubMed
13. [13] Eutamene H, Bradesi S, Larauche M, et al. (2010). Guanylate Cyclase C-Mediated Antinociceptive Effects of Linaclotide in Rodent Models of Visceral Pain. Neurogastroenterol Motil. DOI PubMed
14. [14] Quigley EMM, Tack J, Chey WD, et al. (2013). Randomised Clinical Trials -- Linaclotide Phase 3 Studies in IBS-C -- A Prespecified Further Analysis Based on European Medicines Agency-Specified Endpoints. Aliment Pharmacol Ther. DOI PubMed
15. [15] Sood R, Ford AC. (2013). Linaclotide: New Mechanisms and New Promise for Treatment in Constipation and Irritable Bowel Syndrome. Ther Adv Chronic Dis. DOI PubMed
16. [16] Shah ED, Kim HM, Schoenfeld P. (2018). Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation -- A Systematic Review and Meta-Analysis. Am J Gastroenterol. DOI PubMed
17. [17] Miner PB Jr, Koltun WD, Wiener GJ, et al. (2017). A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients with Chronic Idiopathic Constipation. Am J Gastroenterol. DOI PubMed
18. [18] LINZESS Prescribing Information (2025). LINZESS (Linaclotide) Capsules for Oral Use: Full Prescribing Information. Ironwood Pharmaceuticals / AbbVie / FDA. PubMed
19. [19] Lacy BE, Levenick JM, Crowell MD. (2019). Safety and Tolerability of Linaclotide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation -- Pooled Phase 3 Analysis. Expert Opin Drug Saf. DOI PubMed
20. [20] Layer P, Stanghellini V, Chey WD, et al. (2014). Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults. Drugs. DOI PubMed
21. [21] Waldman SA, Camilleri M. (2018). Guanylate Cyclase-C as a Therapeutic Target in Gastrointestinal Disorders. Gut. DOI PubMed
22. [22] Thomas RH, Luthin DR. (2015). Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation -- Focus on Prosecretory Agents. Pharmacotherapy. DOI PubMed
23. [23] Corsetti M, Tack J. (2013). Linaclotide -- A New Drug for the Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation. United European Gastroenterol J. DOI PubMed
24. [24] Brierley SM, Linden DR. (2014). Neuroplasticity and Dysfunction after Gastrointestinal Inflammation. Nat Rev Gastroenterol Hepatol. DOI PubMed
25. [25] Yu SW, Rao SS. (2014). Advances in the Management of Constipation-Predominant Irritable Bowel Syndrome -- The Role of Linaclotide. Therap Adv Gastroenterol. DOI PubMed